N-(2-(trifluoromethyl)phenyl)acrylamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(2-(trifluoromethyl)phenyl)acrylamide
• 英文别名: N-[2-(trifluoromethyl)phenyl]prop-2-enamide
• 化学式: C₁₀H₈F₃NO
• mdl: MFCD12091152
• 分子量: 215.175
• InChiKey: NHFXQZUVAMCIIX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-(2-(trifluoromethyl)phenyl)acrylamide 在 硫酸 、 硝酸 、 溶剂黄146 作用下， 反应 16.0h， 以12%的产率得到N-[2-nitro-6-(trifluoromethyl)phenyl]prop-2-enamide
  参考文献：
  名称：

  [EN] FERROPORTIN INHIBITORS
  [FR] NOUVEAUX INHIBITEURS DE LA FERROPORTINE

  摘要：

  公开号：

  WO2017068089A9
• 作为产物：
  描述：

  丙烯酰氯 、 邻氨基三氟甲苯 在 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 为溶剂， 生成 N-(2-(trifluoromethyl)phenyl)acrylamide
  参考文献：
  名称：

  N-芳基丙烯酰胺的谷胱甘肽（GSH）反应性的系统研究：1.芳基取代的影响

  摘要：

  靶向共价抑制剂的设计成功与否，部分取决于对亲电试剂反应性影响因素的了解。为了进一步了解N-芳基丙烯酰胺之间的结构-反应关系，我们确定了在11个不同的邻位，间位和对位独立取代的N-芳基丙烯酰胺家族的谷胱甘肽（GSH）反应速率抑制剂设计的共同点。我们发现，取代基对反应速率的影响表明邻位，间位和对位取代具有线性Hammett相关性。此外，我们注意到1 H和13之间的相关性丙烯酰胺与GSH反应速率的C NMR化学位移，表明NMR化学位移可能是相对丙烯酰胺反应性的便捷替代量度。密度泛函理论计算揭示了计算的活化参数与实验确定的反应速率之间的相关性，从而验证了这种方法以预期方式筛选合成候选物的应用。

  DOI：

  10.1021/acs.jmedchem.5b01018

文献信息

• Ferroportin inhibitors
  申请人：Vifor (International) AG

  公开号：US10364239B2

  公开（公告）日：2019-07-30

  The invention relates to novel compounds of the general formula (A-I), with Het-2 being an optionally substituted bicyclic heteroaryl of the formula (AA) pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the use as ferroportin inhibitors, more particularly for the use in the prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, such as particularly iron overload states such as in particular thalassemia and hemochromatosis.

  本发明涉及通式(A-I)的新型化合物，其中Het-2为通式(AA)的任选取代的双环杂芳基。本发明涉及由这些化合物组成的药物组合物及其作为药物的用途，特别是作为铁皮质素抑制剂的用途，尤其是用于预防和/或治疗由缺乏铁皮质素或铁代谢紊乱引起的疾病，如特别是铁过载状态，如地中海贫血症和血色病。
• A Potent Isoprenylcysteine Carboxylmethyltransferase (ICMT) Inhibitor Improves Survival in Ras-Driven Acute Myeloid Leukemia
  作者：Nagore I. Marín-Ramos、Moisés Balabasquer、Francisco J. Ortega-Nogales、Iván R. Torrecillas、Ana Gil-Ordóñez、Beatriz Marcos-Ramiro、Pedro Aguilar-Garrido、Ian Cushman、Antonio Romero、Francisco J. Medrano、Consuelo Gajate、Faustino Mollinedo、Mark R. Philips、Mercedes Campillo、Miguel Gallardo、Mar Martín-Fontecha、María L. López-Rodríguez、Silvia Ortega-Gutiérrez

  DOI：10.1021/acs.jmedchem.9b00145

  日期：2019.7.11

  Blockade of Ras activity by inhibiting its post-translational methylation catalyzed by isoprenylcysteine carboxylmethyltransferase (ICMT) has been suggested as a promising antitumor strategy. However, the paucity of inhibitors has precluded the clinical validation of this approach. In this work we report a potent ICMT inhibitor, compound 3 [UCM-1336, IC50 = 2 mu M], which is selective against the other enzymes involved in the post-translational modifications of Ras. Compound 3 significantly impairs the membrane association of the four Ras isoforms, leading to a decrease of Ras activity and to inhibition of Ras downstream signaling pathways. In addition, it induces cell death in a variety of Ras-mutated tumor cell lines and increases survival in an in vivo model of acute myeloid leukemia. Because ICMT inhibition impairs the activity of the four Ras isoforms regardless of its activating mutation, compound 3 surmounts many of the common limitations of available Ras inhibitors described so far. In addition, these results validate ICMT as a valuable target for the treatment of Ras-driven tumors.
• FERROPORTIN INHIBITORS
  申请人：Vifor (International) AG

  公开号：EP3364967A2

  公开（公告）日：2018-08-29
• NOVEL FERROPORTIN INHIBITORS
  申请人：Vifor (International) AG

  公开号：EP3365339A1

  公开（公告）日：2018-08-29
• Novel Ferroportin Inhibitors
  申请人：Vifor (International) AG

  公开号：US20180297991A1

  公开（公告）日：2018-10-18

  The invention relates to novel ferroportin inhibitors of the general formula (I) pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, such as particularly iron overload states such as in particular thalassemia and hemochromatosis.